Begacestat

Pfizer Begacestat, also known as PF-05212362, is a thiophene sulfonamide γ-secretase inhibitor originally developed at Wyeth for Alzheimer’s disease research. The Begacestat chemical structure contains a 5-chlorothiophene-2-sulfonamide group linked to a chiral hydroxymethyl-containing side chain bearing two trifluoromethyl groups. The Begacestat molecular structure contains a 5-chlorothiophene-2-sulfonamide moiety and two trifluoromethyl groups. Begacestat has a molecular weight of 391.74 g/mol and a reported cLogP of 2.313. This Begacestat reference compound is supplied at 95% purity, with purity validated by NMR and/or LCMS methods, and is sold for research purposes under agreement from Pfizer Inc.  

Application of Begacestat

The defining feature shaping how Begacestat is used in research is its selectivity: it inhibits γ-secretase cleavage of amyloid precursor protein roughly sixteen-fold more potently than Notch receptor cleavage. This matters because earlier, non-selective γ-secretase inhibitors reduced amyloid-β but also disrupted Notch signaling, a pathway tied to the immune and gastrointestinal toxicity that derailed several Alzheimer's drug candidates in clinical development. Begacestat is therefore used less as a general enzyme blocker and more as a tool for isolating APP-dependent effects from Notch-dependent ones, letting researchers evaluate amyloid-lowering strategies without the confound of Notch disruption, and as a reference compound in comparative screens against newer γ-secretase modulators.

In Vitro

In cell-free and cell-based γ-secretase assays, Begacestat lowers Aβ42 and Aβ40 with EC50 values of 12.4 and 14.8 nM, respectively, and displaces a tritiated analog of itself from enriched γ-secretase enzyme complexes at comparable potency, confirming direct enzyme engagement. Cellular Notch cleavage assays show the same roughly sixteen-fold selectivity margin observed biochemically.

In Vivo

In Tg2576 transgenic mice overexpressing human APP, a single oral 5 mg/kg dose of begacestat reduced brain Aβ40 by 37% and Aβ42 by 25% within four hours, alongside parallel reductions in plasma and cerebrospinal fluid Aβ, and reversed contextual fear-conditioning deficits linked to amyloid burden. In healthy human volunteers, single oral doses produced dose-dependent changes in plasma Aβ, confirming that the effect translates from rodent models into humans.

Biochemical and Physiological Actions

The Begacestat structure enables binding within the presenilin-containing γ-secretase complex, where the compound blocks the intramembrane proteolysis step that releases Aβ peptides from APP. Because γ-secretase also processes the Notch receptor at a structurally distinct site, Begacestat's binding mode interferes with APP cleavage while leaving a larger share of Notch processing intact than earlier inhibitors achieved – partial substrate selectivity rather than complete enzyme shutdown.

Features and Benefits of Begacestat

For laboratories studying amyloid pathway biology, Begacestat offers:

• reduced interference from Notch-related effects compared with less selective γ-secretase inhibitors;
• Begacestat (CAS 769169-27-9) supplied at 95% purity, with purity validated by NMR and/or LCMS methods; 
• well-documented Begacestat molecular weight, facilitating compound identification and experimental reference use;  
• reported activity in cell-free, cellular, and Tg2576 mouse models, supporting use across multiple stages of preclinical amyloid-pathway research.